- Home
- Board Member Login
- Advertising
- Useful Links
- Contact Us
- Search
-
SEARCH AATOD
-
 |
Welcome to AATOD’s updated website
I am pleased to welcome you to AATOD’s updated website, which includes pictures from our successful April 2012 National Conference in Las Vegas, Nevada. The conference content was rich, including a number of pre-conference sessions focusing on patient advocacy, Hepatitis treatment in OTPs, increasing access to Medication Assisted Treatment in [...]
There have been a number of recent developments with regard to the FDA, responding to citizen’s petitions from the US pharmaceutical industry. Reckitt Benckiser had submitted a citizen’s petition, requesting that the FDA refrain from approving any buprenorphine drug applications for opioid dependence treatment unless the application included measures to [...]
News Item of the Week
April 12, 2013
There have been a number of recent and critical articles about OTPs in the United States. Some of this media coverage focuses on “for-profit” OTPs in the country, providing unfavorable comparisons to the “non-profit” counterparts.
The April 8, 2013 edition of Alcoholism and Drug Abuse Weekly [...]
Global Addiction and EUROPAD Joint Conference
Register now for the Global Addiction and Europad Joint Conference in Pisa in 5 weeks time. The Conference offers you a high-quality, multi-disciplinary scientific programme with sessions to suit clinical, research and policy influencers.
The full draft conference programme is being added to on a daily basis and can be [...]
Vivitrol/Naltrexone Guidelines
Vivitrol/Naltrexone Guidelines
There are three federally approved medications to treat chronic opioid addiction in the United States: methadone, buprenorphine, and Vivitrol/naltrexone. All three medications can be used as part of treatment for opioid addiction delivered through the federally certified and licensed [...]
Welcome to AATOD’s New Website
We hope you enjoy your visit. We are adding more content but we would love your feedback.
